Shares of Aura Biosciences, Inc. (NASDAQ:AURA – Get Free Report) shot up 1.6% during trading on Wednesday. The company traded as high as $6.41 and last traded at $6.40. Approximately 541,814 shares changed hands during trading, a decline of 4% from the average session volume of 562,662 shares. The stock had previously closed at $6.30.
Analysts Set New Price Targets
AURA has been the subject of several recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aura Biosciences in a report on Monday, October 12th. HC Wainwright dropped their target price on Aura Biosciences from $24.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, August 11th. Finally, Wall Street Zen downgraded Aura Biosciences from a “hold” rating to a “sell” rating in a research report on Sunday, August 16th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $17.50.
View Our Latest Report on Aura Biosciences
Aura Biosciences Price Performance
The stock’s fifty day simple moving average is $6.68 and its two-hundred day simple moving average is $6.69.
Aura Biosciences (NASDAQ:AURA – Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.10). Equities research analysts anticipate that Aura Biosciences, Inc. will post -1.61 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the business. Montanova Capital LLC boosted its position in shares of Aura Biosciences by 64.8% in the 2nd quarter. Montanova Capital LLC now owns 7,206,217 shares of the company’s stock valued at $51,164,000 after purchasing an additional 2,833,333 shares during the period. Frazier Life Sciences Management L.P. raised its holdings in Aura Biosciences by 39.2% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 7,100,000 shares of the company’s stock worth $50,410,000 after buying an additional 2,000,000 shares during the period. BlackRock Inc. acquired a new stake in Aura Biosciences during the 2nd quarter worth about $33,424,000. Nantahala Capital Management LLC acquired a new stake in Aura Biosciences during the 2nd quarter worth about $20,952,313. Finally, Jupiter Topco LLC purchased a new stake in Aura Biosciences during the second quarter valued at about $17,788,000. Institutional investors and hedge funds own 96.75% of the company’s stock.
Aura Biosciences Company Profile
Aura Biosciences, Inc (NASDAQ:AURA) is a clinical-stage biotechnology company developing targeted therapies for cancer. The company’s platform is designed to use tumor-targeting virus-like particles to selectively bind to cancer cells and deliver therapeutic payloads, with the goal of treating tumors while limiting damage to surrounding healthy tissue.
Aura’s lead product candidate is AU-011, also known as belzupacap sarotalocan, an investigational therapy being developed for primary choroidal melanoma, a form of eye cancer.
Read More
- Five stocks we like better than Aura Biosciences
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
